z-logo
Premium
Harnessing T cells to fight cancer with BiTE ® antibody constructs – past developments and future directions
Author(s) -
Klinger Matthias,
Benjamin Jonathan,
Kischel Roman,
Stienen Sabine,
Zugmaier Gerhard
Publication year - 2016
Publication title -
immunological reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.839
H-Index - 223
eISSN - 1600-065X
pISSN - 0105-2896
DOI - 10.1111/imr.12393
Subject(s) - blinatumomab , cancer research , lymphoma , antibody , medicine , immunotherapy , t cell , cancer , cytotoxic t cell , immunology , biology , immune system , cd19 , in vitro , biochemistry
Summary Bispecific T‐cell engager (Bi TE ® ) antibody constructs represent a novel immunotherapy that bridges cytotoxic T cells to tumor cells, thereby inducing target cell‐dependent polyclonal T‐cell activation and proliferation, and leading to apoptosis of bound tumor cells. Anti‐ CD 19 Bi TE ® blinatumomab has demonstrated clinical activity in Philadelphia chromosome (Ph)‐negative relapsed or refractory (r/r) acute lymphoblastic leukemia ( ALL ) eventually resulting in conditional approval by the U.S. Food and Drug Administration in 2014. This drug is currently further developed in pediatric and Ph + r/r, as well as in minimal residual disease‐positive ALL , and might also offer clinical benefit for patients with non‐Hodgkin's lymphoma, especially for those with aggressive forms like diffuse large B‐cell lymphoma. Another Bi TE ® antibody construct in hemato‐oncology designated AMG 330 targets CD 33 on acute myeloid leukemia blast cells. After showing promising ex vivo activity, this drug candidate has recently entered phase 1 clinical development, and has further indicated potential for combination with checkpoint inhibitors. In solid tumor indications, three Bi TE ® antibody constructs have been tested in phase 1 studies so far: anti‐Ep CAM Bi TE ® AMG 110, anti‐ CEA Bi TE ® MEDI ‐565/ AMG 211, and anti‐ PSMA Bi TE ® BAY 2010112/ AMG 212. Pertinent questions comprise how to maximize Bi TE ® penetration and T‐cell infiltration of the tumor while simultaneously minimizing any adverse events, which is currently explored by a continuous intravenous infusion approach. Thus, Bi TE ® antibody constructs will hopefully provide new treatment options for patients in several indications with high unmet medical need.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here